{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:25:47Z","timestamp":1771647947738,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clinthera.2020.12.012","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:11:46Z","timestamp":1610622706000},"page":"396-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration"],"prefix":"10.1016","volume":"43","author":[{"given":"Yi-fan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-jun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-ying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-fang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.12.012_bib1","series-title":"Diabetes Atlas","year":"2019"},{"key":"10.1016\/j.clinthera.2020.12.012_bib2","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/dom.12977","article-title":"Future challenges and therapeutic opportunities in type 2 diabetes: changing the paradigm of current therapy","volume":"19","author":"Owens","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2020.12.012_bib3","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","article-title":"Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2","volume":"61","author":"Ghezzi","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2020.12.012_bib4","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2020.12.012_bib5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2020.12.012_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jphs.2016.02.003","article-title":"Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects","volume":"130","author":"Tahara","year":"2016","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2020.12.012_bib7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/00498254.2015.1113576","article-title":"Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males","volume":"46","author":"Wang","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2020.12.012_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40261-015-0366-7","article-title":"Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus","volume":"36","author":"Yong","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2020.12.012_bib9","doi-asserted-by":"crossref","first-page":"113632","DOI":"10.1016\/j.jpba.2020.113632","article-title":"Characterization and quantitative determination of henagliflozin metabolites in humans","volume":"192","author":"Cheng","year":"2021","journal-title":"J\u00a0Pharm Biomed"},{"key":"10.1016\/j.clinthera.2020.12.012_bib10","first-page":"293","article-title":"Comparative performance of four equations estimating glomerular filtration rate in adult Chinese diabetics","volume":"36","author":"Xu","year":"2013","journal-title":"Endocrinol Invest"},{"key":"10.1016\/j.clinthera.2020.12.012_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40200-015-0133-6","article-title":"Urinary biomarker N-acetyl-\u03b2-D-glycosaminidase can predict severity of renal damage in diabetic nephropathy","volume":"14","author":"Sheira","year":"2015","journal-title":"J\u00a0Diabetes Metab Disord"},{"key":"10.1016\/j.clinthera.2020.12.012_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","article-title":"Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study","volume":"36","author":"Ji","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2020.12.012_bib13","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.12.012_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2020.12.012_bib15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40262-020-00875-1","article-title":"Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor","volume":"59","author":"Fediuk","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.12.012_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.12.012_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.12.012_bib18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40262-015-0285-z","article-title":"Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor","volume":"54","author":"Devineni","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.12.012_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1124\/dmd.112.049551","article-title":"Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects","volume":"41","author":"Miao","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2020.12.012_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5414\/CP203343","article-title":"A\u00a0PK\/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects","volume":"57","author":"Dawra","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2020.12.012_bib21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2020.12.012_bib22","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.clinthera.2013.06.017","article-title":"Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects","volume":"35","author":"Yang","year":"2013","journal-title":"Clin Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820305610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820305610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:55Z","timestamp":1758963295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820305610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0149291820305610"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.12.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}